Work

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-147292

Authors: Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta

Institutions: The University of Texas MD Anderson Cancer Center, Austin Hospital, Austin Health, Levine Cancer Institute, University of California, Davis, Cross Cancer Institute, Peter MacCallum Cancer Centre, Bristol-Myers Squibb (United States), University of Alabama at Birmingham

Language: English

Topic: Phagocytosis and Immune Regulation

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213952290

Cites:

Cited by: 21

Related to: 10